RU2497532C2 - Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения - Google Patents

Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения Download PDF

Info

Publication number
RU2497532C2
RU2497532C2 RU2011127184/15A RU2011127184A RU2497532C2 RU 2497532 C2 RU2497532 C2 RU 2497532C2 RU 2011127184/15 A RU2011127184/15 A RU 2011127184/15A RU 2011127184 A RU2011127184 A RU 2011127184A RU 2497532 C2 RU2497532 C2 RU 2497532C2
Authority
RU
Russia
Prior art keywords
cells
cxcr
compatible
composition
chemotactic activity
Prior art date
Application number
RU2011127184/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2011127184A (ru
Inventor
Эндрю ПЕКОРА
Роберт ПРЕТИ
Original Assignee
Эморсайт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эморсайт, Инк. filed Critical Эморсайт, Инк.
Publication of RU2011127184A publication Critical patent/RU2011127184A/ru
Application granted granted Critical
Publication of RU2497532C2 publication Critical patent/RU2497532C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2011127184/15A 2008-12-03 2009-12-02 Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения RU2497532C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11955208P 2008-12-03 2008-12-03
US61/119,552 2008-12-03
US16985009P 2009-04-16 2009-04-16
US61/169,850 2009-04-16
PCT/US2009/066354 WO2010065601A1 (en) 2008-12-03 2009-12-02 Infarct area perfusion-improving compositions and methods of vascular injury repair

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2013136170/15A Division RU2550959C2 (ru) 2008-12-03 2013-08-01 Композиции, улучшающие перфузию в области инфаркта, и способы восстановления сосудистого повреждения

Publications (2)

Publication Number Publication Date
RU2011127184A RU2011127184A (ru) 2013-01-10
RU2497532C2 true RU2497532C2 (ru) 2013-11-10

Family

ID=42231331

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2011127184/15A RU2497532C2 (ru) 2008-12-03 2009-12-02 Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения
RU2013136170/15A RU2550959C2 (ru) 2008-12-03 2013-08-01 Композиции, улучшающие перфузию в области инфаркта, и способы восстановления сосудистого повреждения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013136170/15A RU2550959C2 (ru) 2008-12-03 2013-08-01 Композиции, улучшающие перфузию в области инфаркта, и способы восстановления сосудистого повреждения

Country Status (10)

Country Link
US (1) US9034316B2 (https=)
EP (1) EP2367432B1 (https=)
JP (2) JP5705127B2 (https=)
CN (1) CN102245189B (https=)
BR (1) BRPI0920976A2 (https=)
CA (1) CA2743255C (https=)
ES (1) ES2640587T3 (https=)
RU (2) RU2497532C2 (https=)
WO (1) WO2010065601A1 (https=)
ZA (1) ZA201104059B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
JP5709880B2 (ja) * 2009-10-23 2015-04-30 アモーサイト インコーポレイテッド 血管の機能不全による進行性心筋傷害治療のための組成物および方法
CN102139095A (zh) * 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
AU2015201990B2 (en) * 2010-08-12 2017-06-22 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
EP2603227B1 (en) * 2010-08-12 2017-10-04 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
US20130096500A1 (en) * 2011-07-07 2013-04-18 Gabor Rubanyi Nucleic acid based cardiovascular therapeutics
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US9533010B2 (en) 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
EP3785767A1 (en) 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
US10111907B2 (en) 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
EP2943206A4 (en) 2013-01-12 2017-01-04 Cesca Therapeutics Inc. Rapid infusion of autologous bone marrow derived stem cells
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
WO2016006782A1 (ko) * 2014-07-08 2016-01-14 라정찬 줄기세포의 보관 안정성 증진용 조성물
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20220378301A1 (en) * 2016-01-04 2022-12-01 Corflow Therapeutics Ag Intracoronary characterization of microvascular obstruction (mvo) and myocardial infarction
CN109790207B (zh) 2016-06-07 2023-06-20 摩登纳特斯有限公司 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途
KR20230035710A (ko) 2017-05-26 2023-03-14 스테미넌트 바이오테라퓨틱스 인크. 폴리글루타민(polyq) 질병에 대한 치료법
CA3080592A1 (en) 2017-10-31 2019-05-09 Modernatx, Inc. Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
WO2020154664A1 (en) * 2019-01-25 2020-07-30 The Johns Hopkins University Predicting atrial fibrillation recurrence after pulmonary vein isolation using simulations of patient-specific magnetic resonance imaging models and machine learning
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
CN111281400B (zh) * 2020-01-22 2022-08-19 首都医科大学宣武医院 借助于非接触式血管可视化设备的辅助操作装置及方法
CN111494606B (zh) * 2020-04-24 2021-12-14 广州医科大学 神经肽y的新应用
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
CN117279650A (zh) 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法
CN112891631B (zh) * 2021-01-29 2021-12-03 江南大学 一种植物源导管及其在修复神经损伤中的应用
CN115205294B (zh) * 2022-09-16 2022-11-22 杭州脉流科技有限公司 一种基于多模型融合的缺血性脑卒中梗死评估装置和方法
CN117305241B (zh) * 2023-11-28 2024-03-19 上海兴瑞一达生物科技有限公司 一种hiPSCs诱导分化为NK细胞的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
FR2596413B1 (fr) 1986-03-27 1988-06-10 Merieux Inst Nouveaux milieux de culture de bacteries appartenant au genre bordetella, contenant des derives etherifies de polymeres de d-glucose, et leur application
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5726152A (en) 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
DE69229454T2 (de) 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
WO1993025216A1 (en) 1992-06-08 1993-12-23 Becton, Dickinson And Company Human primitive stem cells
CA2170357A1 (en) 1993-08-25 1995-03-02 David Digiusto Method for producing a highly enriched population of hematopoietic stem cells
US5628761A (en) * 1994-07-08 1997-05-13 Rizik; David G. Guide wire passage creation device
US20030113304A1 (en) 1995-06-07 2003-06-19 The Trustees Of Columbia University Selective tissue site revascularization by combined focal injury and hematopoietic stem cell introduction
US5810836A (en) * 1996-03-04 1998-09-22 Myocardial Stents, Inc. Device and method for trans myocardial revascularization (TMR)
US8075880B2 (en) 1999-01-11 2011-12-13 Steward St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for regulating angiogenesis
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
CA2311729A1 (en) 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
CA2330208A1 (en) 1998-05-29 1999-12-02 Thomas Jefferson University Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
IL125532A0 (en) 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
US6060317A (en) * 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
CA2341754A1 (en) 1998-08-31 2000-03-09 New York University Stem cells bearing an fgf receptor on the cell surface
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
US6287265B1 (en) 1999-06-23 2001-09-11 Cindy L. Gleason Blood collection kit
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
AU1100001A (en) 1999-10-29 2001-05-14 Children's Hospital Of Los Angeles Gammac negative hematopoietic progenitor cells
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
AU2001250966A1 (en) 2000-03-23 2001-10-03 Stem Cells, Inc. Pluripotential stem cells
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002013760A2 (en) 2000-07-31 2002-02-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
CA2421834A1 (en) 2000-09-11 2002-03-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Use of carp inhibitors for the treatment of heart diseases
JP2005508831A (ja) 2000-10-02 2005-04-07 ザ スクリプス リサーチ インスティテュート 血管新生促進のための方法および組成物
FR2819265B1 (fr) 2001-01-10 2004-01-02 Centre Nat Rech Scient Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques
EP1361896A2 (en) 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
JP2004536794A (ja) 2001-04-09 2004-12-09 メドトロニック、インコーポレイテッド マイクロ遠心機を用いる血液成分の分離方法及びその使用法
ITTO20010517A1 (it) 2001-05-31 2002-12-01 Giulio Alessandri Cellule progenitrici vascolari umane.
WO2003013570A1 (en) 2001-08-09 2003-02-20 Cornell Research Foundation, Inc. Platelet-derived growth factor protection of cardiac myocardium
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
AU2002353465B2 (en) 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
EP1465983B1 (en) 2001-12-21 2010-03-31 Immunex Corporation Endothelial stem cells, populations, methods of isolation and use thereof
AU2003217271A1 (en) 2002-01-29 2003-09-02 A. Mark Colb Endothelialization of vascular surfaces
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
EP1551955A4 (en) 2002-07-16 2006-11-29 Yissum Res Dev Co METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION
PL216193B1 (pl) 2002-07-25 2014-03-31 Scripps Research Inst Wyizolowana, ssacza, pochodząca ze szpiku kostnego linia populacji niezróżnicowanych krwiotwórczych komórek macierzystych
AU2003270051A1 (en) 2002-08-29 2004-03-19 Baylor College Of Medicine Heart derived cells for cardiac repair
US9969977B2 (en) 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
AU2003275326A1 (en) * 2002-09-30 2004-04-23 Massachussetts Eye And Ear Infirmary In vitro culture of tissue structures
US20040136973A1 (en) 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
WO2004052177A2 (en) 2002-12-05 2004-06-24 Case Western Reserve University Cell-based therapies for ischemia
US20040197310A1 (en) 2003-02-12 2004-10-07 Sanberg Paul R. Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction
CN1770976A (zh) 2003-02-13 2006-05-10 人类起源公司 利用脐带血治疗患有疾病、紊乱或状况的个体的用途
DE10347436B4 (de) 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
US7863043B2 (en) 2004-02-11 2011-01-04 Aldagen, Inc. Stem cell populations and methods of use
US20050232905A1 (en) 2004-03-26 2005-10-20 Yeh Edward T Use of peripheral blood cells for cardiac regeneration
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
JP2006115771A (ja) 2004-10-22 2006-05-11 Kyoto Univ 骨格筋由来の心筋幹細胞
WO2006060779A2 (en) 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
WO2006093860A2 (en) 2005-02-28 2006-09-08 Regenetech, Inc. Method and composition for repairing heart tissue
WO2006121532A2 (en) 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
MY147516A (en) 2005-11-07 2012-12-31 Amorcyte Inc Compositions and method of vascular injury repair cross-reference to related applications
JP5738516B2 (ja) * 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
US20080118977A1 (en) * 2006-11-22 2008-05-22 Institut De Recherche En Hematologie Et Transplantation Process to cary out a cellular cardiomyoplasty
JP5709880B2 (ja) * 2009-10-23 2015-04-30 アモーサイト インコーポレイテッド 血管の機能不全による進行性心筋傷害治療のための組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Denq Z., et al. Effects of GM-CSF on the stem cells mobilization and plasma C-reactive protein levels in patients with acute myocardial infarction. Int J Cardiol. 2006 Oct 26; 113(1):92-6. Epub 2006 Aug 7. *

Also Published As

Publication number Publication date
CA2743255C (en) 2014-02-18
RU2011127184A (ru) 2013-01-10
WO2010065601A1 (en) 2010-06-10
US20100143317A1 (en) 2010-06-10
EP2367432B1 (en) 2017-08-30
JP2012510521A (ja) 2012-05-10
CN102245189B (zh) 2015-06-17
JP5705127B2 (ja) 2015-04-22
HK1163542A1 (en) 2012-09-14
BRPI0920976A2 (pt) 2015-08-18
EP2367432A4 (en) 2012-05-02
CA2743255A1 (en) 2010-06-10
RU2013136170A (ru) 2015-02-10
EP2367432A1 (en) 2011-09-28
ZA201104059B (en) 2012-02-29
CN102245189A (zh) 2011-11-16
RU2550959C2 (ru) 2015-05-20
US9034316B2 (en) 2015-05-19
JP2013166803A (ja) 2013-08-29
ES2640587T3 (es) 2017-11-03

Similar Documents

Publication Publication Date Title
RU2497532C2 (ru) Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения
Tang et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction
Nguyen et al. Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors
Kim et al. The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease
Singh et al. Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010–2015)
Leone et al. Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction
JP2012510521A5 (https=)
Michler Stem cell therapy for heart failure
Shan et al. Combination of low-energy shock-wave therapy and bone marrow mesenchymal stem cell transplantation to improve the erectile function of diabetic rats
Zhou et al. Regulatory T cells enhance mesenchymal stem cell survival and proliferation following autologous cotransplantation in ischemic myocardium
Cheng et al. Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies
Shudo et al. Novel regenerative therapy using cell-sheet covered with omentum flap delivers a huge number of cells in a porcine myocardial infarction model
Shafei et al. Mechanistic effects of mesenchymal and hematopoietic stem cells: New therapeutic targets in myocardial infarction
Michler Stem cell therapy for heart failure
JP2013508408A5 (https=)
Li et al. Transplantation of multipotent Isl1+ cardiac progenitor cells preserves infarcted heart function in mice
Tian et al. Combined therapy with atorvastatin and atorvastatin-pretreated mesenchymal stem cells enhances cardiac performance after acute myocardial infarction by activating SDF-1/CXCR4 axis
Fang et al. Enhanced therapeutic effects of mesenchymal stem cells on myocardial infarction by ischemic postconditioning through paracrine mechanisms in rats
Perin et al. Stem cell therapy for cardiac diseases
Li et al. Enhanced human adipose‐derived stem cells with VEGFA and bFGF mRNA promote stable vascular regeneration and improve cardiac function following myocardial infarction
Kocher et al. Stem cells and cardiac regeneration
Abouzid et al. Stem cell therapy for myocardial infarction and heart failure: a comprehensive systematic review and critical analysis
Mohsin et al. Cortical bone derived stem cells for cardiac wound healing
Kovacic et al. Update on the use of stem cells for cardiac disease
Schoenfeld et al. The existence of myocardial repair: mechanistic insights and enhancements